TECHNOLOGY FACTS

Urodynamic Devices Market Segmentation Detailed Study with Forecast to 2022

The World Health Organization (WHO) has estimated over 300,000 patients to be affected with bladder cancer annually around the world. The National Association of Incontinence estimates roughly 200 Mn population across the globe to be suffering from urinary incontinence every year. Incidences such as these have increased demand for urodynamic devices, along with the rise in clinical urgency. Numerous healthcare initiatives have been creating awareness about urological disorders, coupled with availability of diagnostics and treatment for urological problems. Some initiatives among these include “Continence Awareness Week” undertaken by the U.K.’s Continence Foundation, and Japan’s “Let’s Talk and Think About Continence”. These initiatives are depriving people of social stigma, encouraging them to consult physicians. The aforementioned factors will boost growth of the global urodynamic devices market in the upcoming years.

Read Report Summary: https://www.factmr.com/report/168/urodynamic-devices-market

Uroflowmetry urodynamic devices will continue to be sought-after among physicians, and revenues from sales of uroflowmetry urodynamic devices will hold more than one-fourth share on global revenues throughout the forecast period. Significant use of uroflowmetry to diagnose prostate cancer, benign prostatic hypertrophy, urinary blockage, bladder cancer, neurogenic bladder, and bladder dysfunction, are contributing to demand for uroflowmetry urodynamic devices in hospitals and urology clinics globally. In addition, sales of urodynamic catheters are projected to register the fastest expansion in the market through 2022.

Urology clinics will continue to be the fastest growing end-users of urodynamic devices in the global market. Hospitals are estimated to remain the largest end-users of urodynamic devices over the forecast period. North America will account for the largest share of the revenues from urodynamic devices sales in hospitals. Urodynamic devices sales in hospitals are anticipated to account for more than US$ 150 Mn revenues by 2022-end.

Request for Report Methodology: https://www.factmr.com/connectus/sample?flag=RM&rep_id=168

In terms of revenues, North America is projected to remain dominant in the global urodynamic devices market. Growth of the market in this region is mainly attributed to the rise in prevalence of target diseases, along with rapid adoption of urodynamic devices in a large number of healthcare and pharmaceutical centers, diagnostic procedures, and increasing preference of the urogynecologists & urologists for the purpose of urodynamic studies. Fact.MR’s report estimates the market in Asia-Pacific excluding Japan (APEJ) to exhibit the fastest expansion through 2022, which can be attributed to growth in prevalence of urological diseases, increasing disposable income of population, and unmet patient needs in the region.

Key market players mentioned in Fact.MR’s report on the global market for urodynamic devices include Best Medical International Inc., Verathon Inc., LABORIE, CooperSurgical Inc., Dantec Dynamics A/S, Neomedix Systems Pty. Ltd., Medica SpA, Boston Scientific Corporation, and Albyn Medical Ltd.

For a broader and insightful view of the competition landscape, request for the Sample report: https://www.factmr.com/connectus/sample?flag=S&rep_id=168

About Us

Fact.MR’s methodology is robust and comprehensive. We employ a range of tools and assets to develop an all-encompassing coverage of a range of industries. We compile data points at local, country, regional, and global level – our approach to capturing the finest nuances, without losing sight of the bigger picture helps us in developing accurate and reliable forecasts and estimates.

Fact.MR has a standard set of guidelines and standards that help maintain a level of consistency across all of our research offerings. The standardization includes step-by-step documentation of the methodologies and guidelines on the sources that are to be used for incorporation of objective and accurate data.

The standardization also involves use of industry-wide analytical tools, and rigorous quality checks to validate market forecasts and sizes. Our unwavering focus on standardization ensures that clients receive the same quality of research and analysis that Fact.MR is known for.

Contact Us

11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
E: info@factmr.com
Blog: https://theheraldmedia.com/

Aptamers Market Key Facts And Insights On Future Scenario To 2022

According to Fact.MR, the global aptamers market is anticipated to grow at an exponential growth rate to register a CAGR of 25.5% during the forecasted period of 2017 to 2022. The peptide segment reflects higher growth rate as compared to other segments by product type. Peptide segment is anticipated to grow at a very high rate to reflect a CAGR of 30.1% during the period of forecast. The DNA segment grows at a comparatively slow rate, however, is enjoys a higher market share by revenue in 2017. The XNA and RNA segments show similar growth rates.

Read Report Summary: https://www.factmr.com/report/173/aptamers-market

The global aptamers market growth is influenced by factors such as developments in technology, advancements in the research, coupled with an increase in the investments made in the biopharmaceutical and pharmaceutical companies. The technological developments and patent expiration of SELEX is more likely to push the growth of the global aptamers market. Aptamers can be generated at a very rapid rate than antibodies; this makes them even more useful in treating diseases at a higher speed. This aspects favors the growth of the aptamers market. Owing to this aspect, aptamers are widely used in drug discoveries, thereby favoring the growth of the aptamer market.

Diagnostics segment by application has a higher market share by revenue followed by the therapeutics segment. But the research and developments segment by application shows higher growth rate, a bit higher than the diagnostics segment, and is expected to show a CAGR of 26.5% during the forecast period. The diagnostics segment is expected to gain a high BPS by the end of 2022.

Request for Report Methodology: https://www.factmr.com/connectus/sample?flag=RM&rep_id=173

By end user, the academic and research centers segment shows a very high growth rate and is anticipated to register a CAGR of 26.4% during the period of forecast of 2017 to 2022 and gain the highest BPS by the end of 2022. Pharmaceutical companies segment and contract research organizations (CRO) segment show similar growth patterns and hence expected to grow alongside each other throughout the period of forecast. The biopharmaceutical companies segment enjoy a higher market share by revenue and dominate the market by the end user type and also is expected to gain BPS by the end of 2022.

The report has also profiled leading players in the global market for aptamers, which would remain active through 2022. These include companies like Vivonics Inc., TriLink BioTechnologies, LLC, Somalogic, Inc., NeoVentures Biotechnology Inc., Aptus Biotech, Base Pair Biotechnologies, Inc., Aptamer Group, Aptamer Sciences, Inc., Aptagen, LLC and AM Biotech.

For a broader and insightful view of the competition landscape, request for the Sample report: https://www.factmr.com/connectus/sample?flag=S&rep_id=173

Peptides and Heparin Market Increasing Demand with Leading Players to 2026

Although therapeutic peptides were originally developed for replacing their endogenous lack, spectrum of the candidate peptide drugs available is not by far restrained to human peptide pool. With the help of multifarious organisms, bioactive peptides are being discovered through modern tools of peptidomics. A virtually infinite range of potential peptide-based medications await pharmacological characterization. Meanwhile, several methods of peptide synthesis are evolving to enable highly efficient production of extraordinarily long & heavily-modified compounds. Numerous clinical trials associated with peptide drug candidates are currently being conducted, which in turn represents a bright future for peptide-based therapeutics. Vendors of peptide therapeutics have been moving to developing countries on the back of large population base serving as potential clinical subjects. Lenient regulatory guidelines, skilled labor, low manufacturing costs, and low market competition are primary reasons why vendors of peptide therapeutics are outsourcing their manufacturing processes to these countries.

Read Report Summary: https://www.factmr.com/report/378/peptides-heparin-market

The market for heparin will continue to be influenced by increasing prevalence of diseases, which lead to formation of clots. Concerns regarding adulteration had been the cause for the prohibition of bovine heparin by the U.S. FDA. However, extreme shortage of porcine heparin has led the FDA to reconsider introduction of bovine heparin, which in turn has led to a rise in amount of crude heparin. Heparin is increasingly used prior to surgeries, during blood transfusion or dialysis, when blood is collected as a sample, which implies their general use for reducing the blood clotting risk. Apart from surgical applications, heparin is also prescribed for preventing blood clot in patients affected with chest pain or angina. Heparin’s supply chain commences at slaughterhouses, trailed by various workshops that extract basic heparin material, called heparin crude, from the mucous membrane of pig intestine. Heparin crude is then sold to pharmaceutical companies, which post-processing produce heparin.

According to Fact.MR, the global peptide and heparin market is projected to reflect a high single-digit CAGR throughout the forecast period (2017-2026). The peptide and heparin market is estimated to reach nearly US$ 35,000 Mn revenues by 2026-end.

Request for Report Methodology: https://www.factmr.com/connectus/sample?flag=RM&rep_id=378

Hospital pharmacies are expected to remain the dominant distribution channel for peptide and heparin. Revenues from sales of peptide and heparin in hospital pharmacies are anticipated to remain considerably larger than those from retail pharmacies and online pharmacies combined. On the basis of indication, revenues from sales of peptide and heparin for cancer treatment are projected to account for the largest market share by 2026-end. Cardiovascular and metabolic disorder indication will also remain remunerative in the market. Sales of peptide and heparin for central nervous systems indication are expected to register the fastest expansion through 2026.

Liraglutide is expected to remain the most lucrative product in the market, followed by bortezomib and goserelin. Liraglutide sales will exhibit the highest CAGR through 2026. In addition, sales of sodium heparin, lithium heparin and exenatide are projected to register a parallel growth through 2026. Asia-Pacific excluding Japan (APEJ) will continue to be the largest market for peptide and heparin, in terms of revenues. The markets in Europe and North America will also remain lucrative, however revenues from these regions will remain significantly lower than those from APEJ.

Key market participants identified by the report include Eli Lilly, Novo Nordisk, Sanofi, Takeda, Teva, Leo Pharma, Aspen, Pfizer Inc., Abbott Laboratories, Bachem, Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., AmbioPharm, Inc., Hemmo Pharma, Biofer S.p.A, Celsus, and Baxter.

For a detailed industry outlook, Get the Report Sample at: https://www.factmr.com/connectus/sample?flag=S&rep_id=378

Plasmapheresis Market Treatment of the Autoimmune Diseases to Boost Demand

According to U.S. National Library of Medicine, the prevalence rate of TTP is in the range of 1.7 to 11 cases per million population in the U.S. In addition to TTP, increase in prevalence of autoimmune diseases and advancement in plasmapheresis is likely to drive the growth of the market during the assessment period in the U.S. The market in Europe is likely to mimic the U.S. in terms of key driving factors, whereas greater emphasis on boosting healthcare infrastructure is likely to fuel market growth in Asia Pacific excluding Japan (APEJ) and Latin America. In terms of revenues, North America will continue to be a leading market, with U.S. accounting for the bulk of revenues. The U.S. is home to some of the leading companies in the plasmapheresis market, and there is a high emphasis on research and development among universities and institutes. Collaboration between companies and institutions has also contributed to the growth of the market in the region.

Read Report Summary: https://www.factmr.com/report/351/plasmapheresis-market

To give readers detailed insights, the report offers segment-wise analysis on the global plasmapheresis market. The report has been segmented on the basis of product into instruments and disposables. Currently, instruments account for a higher revenue share of the market, and is poised to grow at a CAGR of 5.7% during the forecast period. However, disposables segment is likely to grow at a higher CAGR, owing to which the revenue share of instruments will witness a decline of nearly 7% during the forecast period.

On the basis of end-users, the report has segmented the market on the basis of biopharmaceutical companies, hospitals & clinics, and ‘other end-users’. According to the report, biopharmaceutical companies will account for the leading revenue share of the market. There has been steady demand for plasmapheresis instruments and disposables from the biopharmaceutical industry. Exponential growth of the biotechnology industry is also a macro factor that is pushing the demand for plasmapheresis instruments and disposables.

Request for Report Methodology: https://www.factmr.com/connectus/sample?flag=RM&rep_id=351

The key end-use applications of plasmapheresis market include therapeutic and source plasma collection. The source plasma collection segment is likely to grow at a CAGR of 7.6% and surpass US$ 1 Bn in revenues by the end of the forecast period.

By technology, the key segments of the market include membrane filtration and centrifugation. The membrane filtration segment is likely to grow at a CAGR of 5.5% through 2026, reaching a value of nearly US$ 477 Mn. Some of the leading companies profiled in the report include Haemonetics Corporation, Asahi Kasei Kuraray Medical Co, Ltd., Terumo Corporation, B. Braun Melsungen AG, Baxter International Inc, Baxter International Inc, Kawasumi Laboratories, Inc, and Kaneka Corporation.

To learn more about how the key growth influencers are shaping the market landscape, request for the Sample Report at: https://www.factmr.com/connectus/sample?flag=S&rep_id=351

Tissue Expanders Market Reconstruction Surgeries to Boost Demand

Growth of the global tissue expanders market is mainly bound to various macro-economic and micro-economic factors. Increasing number of breast removal attributed to breast cancer surgeries is projected to rev up demand for tissue expanders globally. World Cancer Research Fund states that breast cancer accounts for nearly 25% of the new cases of cancer and is a common type of cancer globally. Growing need to improve the aesthetic beauty is further expected to contribute towards the global market growth of tissue expanders. Breast tissue expanders continue to remain increasingly preferred and highly popular clinical option among the customers.

Read Report Summary: https://www.factmr.com/report/340/tissue-expanders-market

According to the Aesthetic Society for Aesthetic Plastic Surgery, breast lift procedures and breast augmentation accounts for 56% of the overall cosmetic expenditures performed in 2016. Increasing number of surgeries has led to increasing demand for the reconstruction of scalp and forehead skin globally. These factors are expected to contribute towards the global market growth of tissue expanders during the forecast period.

Increasing number of road accidents lead to various injuries and scars on arms, head, legs and chest. Surge in the number of scars due to increasing number of road accidents is further expected to rev up demand for surgical interventions. According to the World Health Organization, more than 1.25 million people die in road accidents each year. These accidents have significantly led to legs, head, arms and chest injuries globally. Increasing number of road accidents is projected to remain a major factor that has revved up demand for treatment of the accident injuries and scars.

To get Intensive Insights: https://www.factmr.com/connectus/sample?flag=RM&rep_id=340

However, breakage or leakage of the silicon expanders is becoming a major concern for the tissue expansion treatment. Growing requirement of replacing the tissue expanders attributed to increasing leakage and spread of saline in the human body continues to increase demand for tissue expanders globally. Such incidences are expected to inhibit the global market growth of tissue expanders during the forecast period.

As need for reconstructing and uplifting breast arises, demand for anatomical tissue expanders is projected to increase globally. In terms of revenue, the anatomical tissue expanders product type segment is projected to witness robust growth in terms of revenue, recording for more than US$ 100 Mn by 2026-end. Further, the anatomical tissue expanders product type segment is projected to reflect significant CAGR throughout the forecast period.

Major players in the global market of tissue expanders are Sientra Inc., PMT Corporation, Johnson & Johnson, Allergan Plc, Groupe Sebbin, Polytech Health & Aesthetics, AirXpanders Inc., Koken Co. Ltd., Guangzhou Wanhe Plastic Materials and GC Aesthetics.

Check out the Sample Report here: https://www.factmr.com/connectus/sample?flag=S&rep_id=340

Orthopedic Braces and Support System Market Research Estimated to Grow According to Forecasts

Distinguished by the presence of numerous vendors, the global medical beds market is highly competitive in nature. The international as well as regional market players, with their strong market penetration and wide geographic reach, are now focusing on extending their products & services for gaining a competitive edge. However, regional vendors are finding it challenging to keep up with international players in terms of market reach, pricing, quality, and financial resources.

Read Report Overview: https://www.factmr.com/report/310/medical-bed-market

The healthcare sector has been witnessing a gradual inclination towards home-based services, from hospital-based services. This is mainly because healthcare services offered in hospitals, particularly during long duration of stays, are expensive. Long-term home-based healthcare services reduces the overall costs for patients. This has been encouraging manufacturers & suppliers to increase their production capacities, in a bid to provide semi-automated and manual beds for home-based healthcare services.

According to a latest research analysis by Fact.MR, the global market for medical beds will expand at a moderate CAGR during 2017 to 2022. Sales of medical beds across the globe are estimated to exceed US$ 3,000 Mn in revenues by 2022-end.

Based on usage, acute care will account for the largest share of the global medical bed market in 2017, and is further projected to gain an uptick in its market share by 2022-end. Long-term care is also expected to witness a significant usage of medical beds in the near future, with shifting preference of patients towards home-based healthcare services. Sales of medical beds in psychiatric and bariatric care will reflect a sluggish expansion through 2022. Non-intensive care applications of medical beds will account for nearly four-fifth share of the market over 2017 to 2022. Intensive care is likely to gain traction among medical bed applications in the near future, with increasing number of medical emergencies and surgeries fuelling the requirement for post-operative care.

Request for the Sample of the Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=310

Based on product type, electric beds will remain preferred among patients in the global medical bed market, however sales of electric beds will register the lowest CAGR through 2022. Semi-electric beds are expected to witness a steady expansion and will account for nearly US$ 1,000 Mn revenues by 2022-end. Manual beds will also gain significant traction over 2017 to 2022, owing to their wide adoption in healthcare institutions that are devoid of sophisticated healthcare facilities. In addition, healthcare providers in rural regions depend highly on manual beds on the back of shortage in advanced medical facilities, and affordability of manual beds.

North America will expand at the highest CAGR in the global medical beds market during 2017 to 2022, followed by Asia-Pacific excluding Japan (APEJ). This growth of medical bed market in North America is attributed to availability of highly advanced healthcare facilities, along with increased healthcare expenditure in the region. In addition, higher availability of sophisticated hospitals such as super specialty and multi-specialty hospitals in North America will further influence demand for medical beds.

Request for Report Methodology: https://www.factmr.com/connectus/sample?flag=RM&rep_id=310

Medical Flexible Packaging Market Key Facts And Insights On Future Scenario To 2022

Fact.MR, in its new report, anticipates the global medical flexible packaging market to register a moderate growth over the forecast period 2017 to 2022. Sales of medical flexible packaging across the globe are expected to account for over US$ 25,000 Mn revenues by 2022-end.

Read Report Summary: https://www.factmr.com/report/247/medical-flexible-packaging-market

Various advantages are offered by medical flexible packaging, which include easy shipping, low waste, and product protection, along with the capability of lowering the overall weight of packaging by approximately 70%. Medical flexible packaging provides product and price differentiation to consumers, and aids the preservation of medical devices’ health and hygiene value. Huge growth opportunities for pharmaceutical and medical device manufacturers are expected to be witnessed across developing countries, which in turn will drive demand for medical flexible packaging in these regions.

Currently struggling in stagnant but mature markets, with a lot of regulatory barriers, and patent expirations, leading market players are adopting key strategies such as regional expansion, and brand positioning. Flexible packaging manufacturers are focusing on increasing their presence in developing economies, in a bid to benefit themselves from low-cost labor, and enhance their product offerings. These manufacturers are also focusing on diversification and combination of data analytics with the manufactured products, in order to develop new novel technologically driven products.

To get Intensive Insights: https://www.factmr.com/connectus/sample?flag=RM&rep_id=247

Other factors expected to impact the market growth include effective supply chain management, attractive packaging, useful tool for identification & branding, prevention of product damage, and higher efficiency in transporting products. However, factors such as stringent government regulations pertaining to recycling of packaging materials, and use of polymers, are expected to curb growth of the market during the forecast period.

Medical flexible packaging are expected to find the largest application in pharmaceutical manufacturing over the forecast period. In addition, sales of medical flexible packaging products for application in implant manufacturing and contract packaging are poised to register a relatively higher CAGR through 2022. On the basis of product, seals will continue to be dominant in the global medical flexible packaging market, in terms of revenues. High-barrier films are expected to be the second most lucrative product in the market. However, wraps are anticipated to witness the fastest expansion in sales through 2022.

Key players projected to lead the global medical flexible packaging market are Datwyler Holdings, Aptar Group, Inc., Reynolds Group Holdings, Berry Group, Inc., Sonoco Products Company, Coveris Holdings S.A., Catalent, Inc., Becton Dickinson & Company, Constantia Flexibles Group GmbH, Mondi Group Plc, Huhtamaki Oyj, Sealed Air Corporation, Bemis Company, Inc., and Amcor Limited.

Check out the Sample Report here: https://www.factmr.com/connectus/sample?flag=S&rep_id=247

Proliferative Vitreoretinopathy Market Intense Competition but High Growth & Extreme Valuation

With the rise in emphasis on prevention and treatment of proliferative vitreoretinopathy (PVR), a serious ailment that leads to blindness despite repeated treatment, the requirement for vitreoretinal centers has gained importance worldwide. Prevention of PVR development at early stage RRD for preserving visual function in patients has become a primary agenda among medical researchers and clinicians. A recent Fact.MR analysis envisages the proliferative vitreoretinopathy market to reflect a modest 4.0% CAGR during the forecast period (2018-2027).

Read Report Summary: https://www.factmr.com/report/795/proliferative-vitreoretinopathy-market

However, establishment of vitreoretinal centers for the provision of advanced ophthalmological procedures is considered impractical, on account of increasing social security costs – a key challenge faced by nations across the globe. In contrast, remarkable advances have been made in medical equipment, and ultra-wide-field scanning laser ophthalmoscope (Optos) is one such advancement. This equipment facilitates the provision of wide-field, noninvasive, and nonmydriatic images, and is being increasingly employed for diagnosis and follow-up of PVR treatment evaluation.

Advantages of deep learning in classifying Optus images in RRD have been observed to be slight, however the method has been deemed clinically imperative to achieve higher accuracy. It has been observed that multiple non-linear processing layers in deep learning approach can be leveraged for effective prevention and treatment of proliferative vitreoretinWith the rise in emphasis on prevention and treatment of proliferative vitreoretinopathy (PVR), a serious ailment that leads to blindness despite repeated treatment, the requirement for vitreoretinal centers has gained importance worldwide. Prevention of PVR development at early stage RRD for preserving visual function in patients has become a primary agenda among medical researchers and clinicians. A recent Fact.MR analysis envisages the proliferative vitreoretinopathy market to reflect a modest 4.0% CAGR during the forecast period (2018-2027).

Hospital pharmacies are leading consumers in the pharmacy industry. Policymakers are becoming more aware about importance of offering effective pharmacy services coupled with safe and rational use of medications. In case of proliferative vitreoretinopathy, hospital pharmacies are considered to be radical asset of the modern pharmacy sector. They are vital part of hospitals and clinics, ensuring safe, effective, and economic use of drugs. According to the study, hospital pharmacies will continue to account for bulk shares of the market in the period of forecast.

To get Intensive Insights: https://www.factmr.com/connectus/sample?flag=RM&rep_id=795

Injectables will remain preferred over other mode of administrations of proliferative vitreoretinopathy management drugs. Treatment of PVR through intravitreal injectables has been considered beneficial as they delivery drugs directly to retina and vitreous. Simplicity of achieving intravitreal injection by doctors is a key factor driving adoption of this method. Subretinal injection has been gaining ground in the treatment of PVR, as it directly affects the resident cells & tissues in subretinal space. However, requirement for highly proficient and stable operators for subretinal injection continues to prevail as a major concern in the healthcare sector.

Proliferative vitreoretinopathy, an inflammatory fibrotic disease, stems from inflammatory milieu post-RRD, which in turn prevents retinal healing. Several studies aimed at suppressing or preventing the development of PVR are being conducted worldwide, with some of the recent ones elucidating effect of “substance P (SP),” and targeted use of non-steroidal anti-inflammatory drugs such as “lornoxicam.”

Research carried out on lornoxicam has not only demonstrated successful improvement in the condition of retina and choroid, but also reduced frequency of membrane formation significantly. Studies conducted on substance P have revealed that SP has the capability of inhibiting apoptosis, and epithelial-mesenchymal transition (EMT) induced by TNFα caused, thereby suppressing or preventing development of proliferative retinopathy.pathy by further studies.

Check out the Sample Report here: https://www.factmr.com/connectus/sample?flag=S&rep_id=795

Neonatal Monitoring Equipment Market to Witness Excellent Long-Term Growth by 2028

Recent Fact.MR report envisages the neonatal monitoring equipment market to record a steady 5.7% CAGR during the forecast period (2018-2028). Over 1,070,000 neonatal monitoring equipment are pegged to be sold worldwide by 2028-end. Prominent players operating in the market such as Medtronic Plc, Natus Medical, Inc., Koninklijke Philips NV, and others, are upgrading their portfolio to make it cost-effective, maintain hospital-to-home point-of-care (PoC) continuum, and incorporate value-added services.

Read Report Summary: https://www.factmr.com/report/746/neonatal-monitoring-equipment-market

North America continues to stay at the vanguard of the neonatal monitoring equipment market, with an estimated market value share of over one-third through the period of forecast. Rate of premature birth has been steadily rising in North America over the past couple of years, according to the CDC, which in turn has increased the number of NICU admissions, thereby creating demand for neonatal monitoring equipment.

Speciality of hospice and palliative medicine has gained significant recognition in North America, with attendant increase in training programs at both academic and clinical level. The imperative role of palliative care in improving growth development outcomes in newborn babies has been highly recognized in the region’s NICUs for reducing the infant and neonatal mortality rates.

Ventilators are set to prevail as preferred product among end-users of neonatal monitoring equipment, and will continues to account for bulk value shares of the market. Recent FDA approvals of new, patient-triggered ventilators, and neurally-adjusted ventilator assist (NAVA), for non-invasive and invasive ventilation related to neonates will augur well for sales of ventilators in the forthcoming years. Additionally, availability of several ventilation modes and strategies for assisting ventilation optimization, and preventing ventilation-induced lung injury will fuel ventilator sales.

To get Intensive Insights: https://www.factmr.com/connectus/sample?flag=RM&rep_id=746

Standalone modality of neonatal monitoring equipment will continue to spearhead the market in terms of value share. This is mainly because standalone devices enable clinicians in offering care delivery even while the hospital’s electronic medical records are in their downtime. However, relatively faster sales expansion has been foreseen for portable neonatal monitoring equipment through 2028. Manufacturers are offering cost-effective portable neonatal monitoring equipment that enable uninterrupted monitoring at the bedside and during in-hospital transport. Growing development of easy-to-use, compact and light portable devices will further fuel their sales in the upcoming years.

Hospitals across the globe are entering into partnership with leading neonatal monitoring equipment manufacturers, in bid to offer family-centered neonatal care of highest quality. Developing advanced NICUs at their core, hospitals are focusing on the provision of supportive, and safe environment for accommodating ongoing family contact, and reducing neonatal stress. These instances point at increased demand for various neonatal equipment, and monitoring equipment are no exception. With the forecast value share of nearly 40% by 2028-end, hospitals will continue to lead the neonatal monitoring equipment market.

Check out the Sample Report here: https://www.factmr.com/connectus/sample?flag=S&rep_id=746

Prefilled Syringes Market Inclinations & Development Status Highlighted for the Forecast Period 2017-2026

According to Fact.MR analysis on prefilled syringes, the global market for prefilled syringes is anticipated to expand at a meteoric rate during the period of forecast. The global prefilled syringes market is poised to grow at a volume CAGR of 9.1% during the period of assessment, 2017-2026 and the sale of prefilled syringes across the globe is estimated to cross US$ 11 Bn by end of the year of assessment (2026).

Read Report Summary: https://www.factmr.com/report/603/prefilled-syringes-market

Manufacturers are focused on developing enhanced prefilled syringe systems to cater to the growing demand for these injectable drug delivery systems. For instance, Becton Dickinson has developed PosiFlush prefilled syringes with a 4% sodium citrate lock solution that can reduce the number of catheters for hemodialysis by about exchanged per 1000 days by about 59% thus minimizing risks.

The research report on global prefilled syringes market has profiled many such key companies involved in the manufacturing of prefilled syringes, such as Unilife Corporation, Sterinova, SHL Group, NIPRO, Bespak, AptarGroup, West Pharmaceutical Services Inc., Vetter Pharma International GmbH, Stevanato Group, SCHOTT AG, Gerresheimer, Medtronic, Baxter International Inc., Terumo Medical Corporation and Becton Dickinson and Company.

North America in terms of sale of prefilled syringes tops other regional market during the period of assessment. This regions, especially dominated by United States, has witnessed increased adoption of glass prefilled syringes owing to high presence of chronic disorders. On the other hand, Asia Pacific excluding Japan (APEJ) region is expected to showcase increased inclination towards these injectable drug delivery systems. Asia Pacific excluding Japan region has shown immense potential as a favorable market place for various end use industries owing to its huge business potential. This has increased the presence of various pharmaceutical industries in the region. Moreover, increasing population growth in China and India, along with aging population has raised the demand bar for prefilled syringes to inject drugs to treat diseases such as diabetes and other autoimmune disorders.

Request for Report Methodology: https://www.factmr.com/connectus/sample?flag=RM&rep_id=603

By material type, glass based prefilled syringes hold the highest market share and sales of glass based prefilled syringes is estimated to surpass U$ 7.5 Bn by end of 2026. However, owing to high fragile nature of these syringes, manufacturers have developed polymer based prefilled syringes that are also gaining high traction. Polymer based prefilled syringes have a comparatively higher break resistance and do not react with the drug they carry.

By technology type, sale of conventional prefilled syringes is higher than safety prefilled syringes. However, rate of sales of safety prefilled syringes is expected grow at a higher pace than the conventional product during the period of forecast.

With increasing demand for efficient drug delivery systems, especially for injectable drug delivery, the need for innovative injectable drug delivery options has risen. Given the advantages of standalone drug injecting systems such as prefilled syringes, such as ease in use and enhanced safety, their demand is expected to increase at a high pace in the coming years.

For a detailed industry outlook, Get the Report Sample at: https://www.factmr.com/connectus/sample?flag=S&rep_id=603